Leramilimab
(Anti-human LAG3 mAb, human IgG4P-Kappa; LAG-525; IMP701)
Catalog No.: PC-Ab1102Not For Human Use, Lab Use Only.
LAG525 (Leramilimab) is a high-affinity, ligand-blocking monoclonal antibody that targets LAG3 and blocks interaction with MHC class II molecules, leading to enhanced T-cell response to tumor cells and decreased tumor growth. LAG525 blocks binding of LAG-3, a negative regulator of T-cell signalling, to MHC class II on tumour cells, which renders the tumour microenvironment less immunosuppressive, and may therefore enhance the activity of PD-1 blockade..
LAG525 (Leramilimab) is a high-affinity, ligand-blocking monoclonal antibody that targets LAG3 and blocks interaction with MHC class II molecules, leading to enhanced T-cell response to tumor cells and decreased tumor growth. LAG525 blocks binding of LAG-3, a negative regulator of T-cell signalling, to MHC class II on tumour cells, which renders the tumour microenvironment less immunosuppressive, and may therefore enhance the activity of PD-1 blockade.
Physicochemical Properties
M.Wt
Formula
Human IgG4P-Kappa
Appearance
Solid
CAS No.
Storage
Solide Powder
-20 °C 12 Months; 4°C 6 Months
In Solvent
-80 °C 6 Months; -20°C 6 Months
Shipping
Solubility
PBS, pH 7.0
Contains no stabilizers or preservatives
